USFDA clearance may strengthen Cipla

Cipla on Thursday said that it has received the Establishment Inspection Report for its Goa plant from the United States Food and Drug Administration, indicating closure of the inspection. The inspection by the USFDA was conducted between January 21 and 28. Goa is home to Cipla’s largest plant as regards USFDA-compliant operations. The Goa unit contributes about 25 per cent of its total US sales in terms of filings, etc. Shares of Cipla may react positively to this development.